Axol Bioscience Ltd.

Axol Bioscience will be attending the 35th International Symposium on ALS/MND in December and presenting a new poster titled "Characterization of human iPSC-derived motor neuron disease model for ALS drug discovery". Human iPSCs continue to make their way onto the lab research bench, and as key drivers in the field, we are excited to be attending the 35th International Symposium on ALS/MND, on 6th-8th October in Montreal Canada to share about our work including the our axoCells ALS Toolbox. Our team will be on Booth 11, flying the flag for human iPSCs and how we're supporting the ALS drug discovery industry at large. One of our scientists will also be presenting a poster showing some of the recent developments related to ALS here at Axol: Poster: Characterization of human iPSC-derived motor neuron disease model for ALS drug discovery (presented by Adele Etienne) Come and talk to us if you are interested in hearing how our axoCells can power your ALS drug discovery models and support your research needs! Alternatively, you can also email us at [email protected]. Download the axoCells ALS Toolbox brochure: https://hubs.la/Q02Yc_Fb0 #ALS #humaniPSCs #drugdiscovery #collaboration #ALSMontreal

Join us?next week Wednesday?at?4pm (BST) for the 2nd?part of our 2-part live webinar series?"The challenge of reproducing complex disease models in iPSC-derived cells? Axol’s development of complex disease models" presented by Dr. Steven Broadbent. Thanks to everyone who joined the first part of the webinar series on Wednesday! The?2nd?part of?this?2-part live webinar series?will be happening on LinkedIn same time next week. In this webinar,?Dr. Steven Broadbent will be detailing some of the practical case studies we have done specifically in Amyotrophic Lateral?Sclerosis (ALS)?and Alzheimer's Disease?(AD)?in creating more complex physiologically relevant human disease models?using iPSCs. Dr. Steven Broadbent?is the Senior Scientific Support Manager here at Axol Bioscience. With a background in neuroscience, 20 years experience as an Electrophysiologist in the?cardiac, neuronal,?and?epithelial?spaces, and 6 years at Axol, Steven brings a wealth of expertise to this presentation. By showcasing our hands-on experience and proven methodologies, we can provide valuable insights into how iPSC-derived models can be leveraged for studying such complex diseases, optimizing experimental workflows, and accelerating drug development. This webinar will offer a unique opportunity for you to learn from practical examples, and explore how iPSCs can enhance the human relevance of your own research. We look forward to sharing our work and journey so far in supporting the development of better?in vitro?models for neurodegenerative diseases such as ALS and AD. Register below. Not able to make it? Don't worry, you can still reach out to us at?[email protected]. We'll be happy to have a conversation. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease?#ALS #linkedInlive

An interview with Axol Bioscience Chief Scientific Officer, Ashley Barnes, from ELRIG Drug Discovery 2024 We are pleased to announce that we have published an exclusive interview with our Chief Scientific Officer, Ashley Barnes, which took place during the ELRIG Drug Discovery conference back in October. Key topics discussed in this interview were: ? An overview of Axol Bioscience. ? The "why" behind our ALS toolbox and what it comprises of. ? Recent developments and trends in the industry as it relates to iPSCs. ? What sets us apart from other companies that offer similar services. This interview offers valuable insights into our work and showcases our ongoing efforts to support the industry building better human models of diseases. To read Ashley's full interview, click here: https://hubs.la/Q02Yd79Q0 To find out more about our axoCells ALS toolbox, download our latest ALS brochure by visiting the following link: https://hubs.la/Q02Yd7sK0 If you would like to discuss how you can use our iPSC-derived cells to fuel your ALS research, contact us at [email protected]. #ELRIG2024 #DrugDiscovery #ScientificAdvancements #Biopharma #ALS

Fuel your?in vitro?dry AMD models?with our?human iPSC-derived RPE cells, and build a robust and relevant tool for your?drug screening?campaigns and?Hit/Lead?validation. iPSC-derived?RPEs?are unique tools for retinal pigment epithelium cell research, retina-linked disorders research, pharmacology, toxicology and drug discovery. Key highlights of our iPSC-derived RPE cells include: ·??????Exhibit?typical?pigmented and cobblestone?morphology ·??????Display the key?phenotypic?and?functional?characteristics of primary human RPE cells including key marker expression (MITF, ZO-1, PMEL17) and?phagocytosis ·??????Display a normal?karyotype?with high genomic stability ·??????Can be used to fuel advanced in vitro models for toxicology testing, dry AMD research and drug discovery ·??????Available in bulk quantities with excellent batch-to-batch and inter-batch reproducibility To find out why we are the first choice for iPSC-derived RPE cells, click here: https://lnkd.in/eRMAeaeX Download our Focus on AMD brochure: https://lnkd.in/e8VtFbbt Looking to build human-relevant?dry AMD?models?for research or drug discovery? Let's have a conversation!?[email protected] #RPEcells #iPSCs #DryAMD

Given the complexity of neurodegenerative diseases, how do we accurately replicate them in an?in vitro?setting??Join our upcoming 2-part webinar?where we tackle this question. As we know, neurodegenerative diseases are a major global health issue, yet the drug development process is notoriously slow with 99.6% of potential new therapies for?Alzheimer's Disease?(AD) alone failing and thus, not reaching the market. With such high failure rates, there is an urgent need for better human-relevant models of such diseases in order to de-risk drug discovery and improve the bench-to-clinic translation gap. However, the complex neuroregulatory environment poses the question as to whether it is possible to model these diseases?in an?in vitro?setting?while still ensuring they remain physiologically relevant. In an upcoming 2-part webinar, starting on Wednesday 20th November, our Senior Scientific Support Manager Dr. Steven Broadbent will be speaking about how iPSCs can be used to achieve this. In the first webinar, he will discuss how we are using iPSCs to build these human-relevant models and how previously we have used them to build?in vitro?models to answer some specific disease-related questions. He will also speak about the challenge of translating these iPSCs into more complex models. In the second webinar, he will be detailing some of the practical case studies we have done specifically in Amyotrophic Lateral Sclerosis and Alzheimer's Disease in creating these more complex physiologically relevant human disease models. Be a part of the discussion by registering for this live event below. If you have any questions, contact us at?[email protected]. #iPSCs #ComplexDiseaseModels #Webinar

Advancing Cardiac Research with iPSCs: a review highlights the utility of iPSCs in Congenital Heart Defect (CHD) research, the molecular pathways involved in the differentiation of cardiomyocytes, and their applications in CHD disease modeling. It was great to see a review on the growing role of human pluripotent stem cells (iPSCs) in modeling congenital heart defects (CHDs). This paper discussed how iPSCs have become an invaluable tool for investigating the genetic and functional variations underlying CHD, offering a more precise and human-relevant approach compared to traditional animal models. The review focused on the differentiation of cardiomyocytes from iPSCs, detailed the molecular pathways involved and the applications of these models in disease modeling, drug discovery and the development development of targeted therapeutics for CHD. The ability to model disease-specific traits in patient-derived cells holds significant promise for advancing cardiac research, and improving outcomes in cardiac care. At Axol, we remain at the forefront of iPSC technology, providing high-quality iPSC-derived cardiac cells that are critical for advancing cardiac research and it is great to see how this review further demonstrates the potential of iPSCs in advancing our understanding of cardiac disease and drug development. To read more, click here: https://hubs.la/Q02YcTCw0 If you would like to discuss how you can use our iPSC-derived cells to develop human-relevant models for your drug discovery and research, contact us at [email protected]. #iPSCs #CardiacResearch #CHD #DiseaseModeling #StemCellResearch #Biotechnology #Axol #DrugDiscovery

Join us today at 4pm (BST) for the first part of our 2-part live webinar series titled "The challenge of reproducing complex disease models in iPSC-derived cells. Axol’s development of complex disease models" presented by Dr. Steven Broadbent. In this LinkedIn live event, we will cover: ·??????iPSCs and the pursuit of ‘more human relevant’ models ·??????Building in vitro models – best practice around lines, cells, assays ·??????The challenge of translational relevance of iPSCs in more complex disease models We look forward to sharing our work and journey so far in supporting the development of better?in vitro?models for neurodegenerative diseases such as Alzheimer's Disease and ALS. It is not too late to register. Register below. Not able to make it? Don't worry, you can still reach out to us at?[email protected]. We'll be happy to help. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease?#ALS #linkedInlive

Are you struggling with your cardiac MEA data? Are your recordings just not very clear? Try this cell seeding tip given by Dr Jamie Bhagwan, one of our Scientific Group Leaders here at Axol. Well, it's #TechTuesday which means it's time for another technical tip from one of our scientists here at Axol to help you! Dr Jamie Bhagwan, one of our Scientific Group Leaders at Axol who specializes in our IPSC-derived cardiomyocytes, shares his top technical tip which relates to seeding cardiomyocytes for MEA analysis. MEA analysis is a tool used to record electrical activity from multiple cells simultaneously, making it particularly valuable for studying cardiomyocytes. When seeding cardiomyocytes on a MEA, the placement of the cells is crucial for obtaining accurate electrical recordings. His top tip is to seed the cardiomyocytes on the central 16 electrodes for the well. These electrodes help to capture the electrical activity of the cardiomyocytes, providing high-quality data. To do this, you need to seed between 8-10 microlitres in the centre of the well making sure it doesn't touch the bottom of the well, thus allowing the cells to gently settle down without being pressed directly against the electrode surfaces. This ensures that all the cells are on the electrodes and not on the outer reference electrodes which are typically used for reference measurements and not for recording the active electrical signals from the cardiomyocytes. This method ensures that the cardiomyocytes are positioned directly on the active electrodes and maximizes the likelihood of capturing strong electrical signals from the cells, leading to better quality data. At Axol, we've spent more than a decade at the forefront of iPSC technology, adding to our bank of expertise in using iPSC-derived cells for drug discovery and research. As such, we're always ready to help. If you are interested in using human iPSC-derived cells to fuel your cardiovascular research, contact us at [email protected]. #TechTuesday #iPSCs #StemCells #Cardiomyocytes

Join us tomorrow at 4pm (BST) for the first part of our 2-part live webinar series titled "The challenge of reproducing complex disease models in iPSC-derived cells? Axol’s development of complex disease models" presented by Dr. Steven Broadbent. Dr. Steven Broadbent is the Senior Scientific Support Manager here at Axol Bioscience. With a background in neuroscience, 20 years experience as an Electrophysiologist in the?cardiac, neuronal,?and?epithelial?spaces, and 6 years at Axol, Steven brings a wealth of expertise to this presentation. His extensive background uniquely positions him to share invaluable insights, offering a deep understanding of the use of iPSCs in neuroscience research that will not only inform but also inspire others to learn and grow. In this LinkedIn live event, he will cover: ·??????iPSCs and the pursuit of ‘more human relevant’ models ·??????Building in vitro models – best practice around lines, cells, assays ·??????The challenge of translational relevance of iPSCs in more complex disease models At Axol, we've spent more than a?decade?at the forefront of?iPSC technology, adding to our bank of?expertise?in using iPSC-derived cells for?drug discovery?and?research.?As such, we're?always?ready to?help?and provide more insight into the application of iPSCs to drive research forward. We look forward to sharing our work and journey so far in supporting the development of better?in vitro?models for neurodegenerative diseases such as Alzheimer's Disease and ALS. It is not too late to register. Register below. Not able to make it? Don't worry, you can still reach out to us at?[email protected]. We'll be happy to have a conversation. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease?#ALS

Given the complexity of neurodegenerative diseases, how do we accurately replicate them in an?in vitro?setting??Join our upcoming 2-part webinar?where we tackle this question. This week Wednesday, we will be having the first of our 2-part webinar presented by our?Senior Scientific Support Manager?Dr.?Steven Broadbent. In this first webinar, he will be discussing how we at Axol, are using iPSCs to build these human-relevant models for such complex neurodegenerative diseases like Alzheimer's Disease. He will also be speaking about how we have used them to build?in vitro?models to answer some specific disease-related questions and the challenge of translating iPSCs into more complex models. Be a part of the discussion and have the opportunity to ask questions by registering for this LinkedIn live event below. If you have any questions, contact us at?[email protected]. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease?#ALS